Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insulet Corporation

https://www.insulet.com/

Latest From Insulet Corporation

ADA 2022 Wrap Up: Iterative Progress On Glucose Control, No Big Surprises

The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.

Diabetic Care Clinical Trials

Dexcom Rumored To Be In Talks To Acquire Insulet

Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.

M & A Deals

Senseonics Projects Slow Growth In 2022 Despite FDA Approval Of Eversense E3 CGM

Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.

Approvals Sales & Earnings

Minute Insight: Insulet Launches Long-Awaited Omnipod 5 Tubeless Insulin Pump

Omnipod 5 is the first tubeless automated insulin delivery system compatible with Dexcom’s G6 continuous glucose monitoring system to automatically adjust insulin levels.

Minute Insights Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Insulet Canada Corporation
    • Neighborhood Diabetes
    • Neighborhood Holdings, Inc.
UsernamePublicRestriction

Register